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This monograph is dedicated to the memory of Dr. Jared James Grantham (1936-
2016), a wonderful man, a compassionate physician, a passionate researcher, and 
an exceptional scientist. Without his vision, achievements and impact on countless 
collaborators and disciples, the field of Polycystic Kidney Disease would not be 
where it is today. His intellect, tenacity, modesty and kindness continue to be an 
inspiration to all. 
Dr Grantham was born in 1936 in Dodge City and grew up in Pratt and Johnson City, 
Kansas. Very young, he learned to overcome adversity when he was affected by 
poliomyelitis and was left with residual right shoulder weakness.  The family 
physician who diagnosed him became his mentor and spurred his interest in 
science and medicine. After high school, he attended college at Baker University in 
Baldwin City, Kansas, with a full scholarship. There he met Carol Elaine Gabbert who 
became his wife after the senior year.  He was accepted to Medical School at the 
University of Kansas Medical School. Between his freshman and sophomore year, 
his interest in science led him to work with Dr. Paul R. Schloerb, a surgeon 
interested in the treatment of kidney failure, and to his first publication on “Acute 
Magnesium Depletion and Excess Induced by Hemodialysis” in the American 
Journal of Physiology in 1960 (1).  
Having savored the joy of medical research and decided that this was how he 
wanted to spend his life, “From Fish to Philosopher” by Homer W. Smith became 
his Bible. After a residency in Internal Medicine at the University of Kansas (1962-
1964), he was accepted for a two-year research fellowship in the National Heart 
Institute's Laboratory of Kidney and Electrolyte Metabolism under the mentorship 
of Robert W. Berliner, Jack Orloff and Maurice B. Burg. During these two years, he 
perfected the microdissection of renal tubules without enzymatic digestion, 
developed a pipette to collect urine from microperfused tubules, discovered that 
the collecting duct was the site for the action of vasopressin to concentrate the 
urine, and that this effect was mediated by cyclic AMP (2-3). He stayed as a staff 
investigator at the National Institutes of Health for three additional years during 
which he showed with Charles E. Ganote how water flows through the cellular layer 
of collecting ducts (4-5) and demonstrated with Maurice B. Burg that the collecting 
duct was the site of the sodium-potassium exchange process critical to maintain 
potassium balance (6).  
In 1969, he moved to the University of Kansas and established his renal research 
laboratory. He became Director of Nephrology in 1970, a position he held for 25 
years.  In 1972, he made the startling discovery that mammalian proximal tubules 
could secrete as well as reabsorb fluid (7-8). Fluid secretion was a tubule function 
believed to function only in lower, aquatic animals lacking glomerular filters. 
Inspired by the memory of Ronnie Wilkerson, a friend from childhood with 
polycystic kidney disease, and working in a clinical environment, he associated the 
discovery of tubule fluid secretion with the mechanism by which cysts derived from 
renal tubules might fill with fluid. 
After 1972, understanding the pathogenesis of Polycystic Kidney Disease and 
eventually finding a cure became Dr. Grantham’s passion.  The initial research 
highlighting the ultrastructure of human renal cysts led him to conclude that cysts 
are unusual benign neoplasms whose mass was due primarily to fluid rather than 
cells (9). He found that most cysts are disconnected from the parent tubule, 
meaning that fluid secretion is the only mechanism by which fluid can enter the 
cysts (10). Next, he discovered that cyclic AMP and hormones stimulating the 
production of this second messenger are powerful agonists of fluid secretion by 
Madin-Darby canine kidney (MDCK) cells as well as by cells cultured from human 
cysts (11-12).  In a landmark study, he showed fluid secretion into intact cysts 
dissected from human polycystic kidneys in a way that was dependent on the 
sodium pump and was stimulated by cyclic AMP (13).  He subsequently 
demonstrated that fluid secretion by mural epithelial cells of human cysts was also 
dependent on the transport of chloride into the cysts through the cystic fibrosis 
transmembrane conductance regulator (CFTR) channel activated by cyclic AMP 
(14).  
Collaborations with James P. Calvet and colleagues at the Kansas University 
discovered that renal cysts expressed increased levels of proto-oncogenes, in 
keeping with their putative neoplastic nature (15-18).  In the light of its new-found 
role in promoting fluid secretion, they investigated the effect of cyclic AMP and 
cyclic AMP agonists on the proliferation of normal renal epithelial- and cyst-derived 
cells (19-21).  They were surprised to learn that cyclic AMP agonists inhibited cell 
proliferation in cells from normal kidneys, but stimulated proliferation in mural 
cells from human polycystic kidney cysts by activating the ERK signaling pathway. 
Later they showed that the treatment of wild-type collecting   duct  cells  with  
calcium  channel   blockers   replicated   the  abnormal proliferative response of the 
ADPKD cells to cyclic AMP, while treatment of ADPKD cells with calcium ionophores 
or calcium channel activators corrected the proliferative phenotype of the cystic 
epithelium. These observations suggested a direct link between the putative role 
of the polycystin complex as a calcium channel and the abnormal proliferative 
response to cyclic AMP of the cystic epithelium. 
The work of the Polycystic Research Program initiated by Dr. Grantham provided a 
strong rationale for the therapeutic targeting of cyclic AMP signaling. An initial 
observation by Vincent Gattone with the vasopressin V2 receptor antagonist 
mozavaptan in the cpk mouse, later confirmed in orthologous rodent models of 
ADPKD, led to clinical trials and finally the approval of Tolvaptan to treat rapidly 
progressive autosomal Dominant Polycystic Kidney Disease in multiple countries 
including the USA in April 2018. It also provided the rationale for the utilization of 
long-acting somatostatin analogs for severe polycystic liver disease.    
Because the decline of renal function occurs late in the clinical course of ADPKD, 
glomerular filtration rate is not an optimal endpoint for clinical trials. This is 
particularly true at early stages of the disease when effective treatments are likely 
to be most beneficial. To evaluate the effect of cyst ameliorating drugs it was 
necessary to find an earlier biomarker of disease progression.  Early in the path 
towards the development of effective treatments for ADPKD, Dr. Grantham was 
the first to propose, in an article published in 1981, that the progression of ADPKD 
could be quantified by changes in kidney volume at early stages of the disease when 
measurements of glomerular filtration rate are not informative (22). Afterwards, 
he was the strongest advocate of kidney volume not only as a prognostic biomarker 
but also as a surrogate endpoint in clinical trials for this disease. Thanks to his vision 
and leadership, the NIH sponsored the Consortium of Radiologic Imaging Studies of 
PKD (CRISP), a twenty-year, large observational study of ADPKD which has become 
the best source of accurate information on the natural history of ADPKD, and the 
PKD Foundation sponsored the PKD Outcomes Consortium (PKDOC) (23). These 
studies led to the qualification of total kidney volume as a prognostic biomarker in 
ADPKD by the Food and Drug Administration and the European Medicines Agency. 
The importance of TKV as a prognostic biomarker and as an endpoint has been 
shown in the two largest clinical trials for ADPKD, in both of which Dr. Grantham 
has been a leading investigator (24-25).  
Although ADPKD is the leading monogenic cause of end-stage kidney disease 
(ESKD) accounting for 5-10% of ESKD cases, public awareness and interest of 
scientists and the NIH in this disease, when Dr. Grantham initiated the Polycystic 
Kidney Disease Program at the University of Kansas, were very low.  He often 
referred to Polycystic Kidney Disease as the Rodney Dangerfield disease because it 
got no respect. Therefore, in 1982, with the help of Joseph Bruening, a Kansas 
business man, he created in Kansas City, the Polycystic Kidney Research Foundation 
(later renamed Polycystic Kidney Disease Foundation). The Foundation has greatly 
accelerated the pace of research on Polycystic Kidney Disease by increasing public 
awareness, attracting scientists to this field of research, and stimulating grant 
portfolios dedicated to this disease by various funding agencies in the USA and 
world-wide. 
Beyond Polycystic Kidney Disease, Dr. Grantham made many other contributions 
to Nephrology, was the founding Editor of the Journal of the American Society of 
Nephrology, served as Secretary-Treasurer of the Society, and was the founding 
Director of the Kidney Institute of the University of Kansas. He has been the 
recipient of numerous awards and recognitions. From the American Society of 
Nephrology, he received the Homer Smith Award in 1992 and the John P. Peters 
Award in 2011. He was the recipient of the Lillian Jean Kaplan International Prize 
for Advancement in the Understanding of Polycystic Kidney Disease from the 
International Society of Nephrology and the PKD Foundation; the Jean Hamburger 
Award from the International Society of Nephrology; the David Hume Award from 
the National Kidney Foundation; and the Scientific Council’s Distinguished 
Achievement Award and the Award of Merit from the American Heart Association. 
Dr. Grantham was designated a University of Kansas Distinguished Professor and 
the Harry Statland Professor of Nephrology. 
In addition to his devotion to his wife Carol, children and grand-children and his 
love for nephrology, Jared had diverse interests and talents, including singing and 
writing children’s books and poetry. He had a full and exciting life which he 
delightfully captured in the inspirational, entertaining and humorous 
autobiography “Why I Think About Urine”.  
On behalf of all the contributors to this special issue on ‘Cellular signaling in PKD’, 
we are honored to dedicate these articles to Jared’s memory in recognition of his 
many contributions but especially his seminal role as the ‘Father of PKD research’. 
                                                                                                                                       
Vicente E. Torres 
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